



# HIV PREVENTION

REVIEW MEETING 2021

**VIRTUAL MEETING** 2 JUNE 2021

## PROGRAM BOOK



# Table of Contents

<b>Welcome</b>	<b>2-3</b>
<b>Practical Information</b>	<b>4</b>
<b>Program</b>	<b>5-7</b>
<b>Accreditation</b>	<b>8</b>
<b>Faculty</b>	<b>9-15</b>
<b>Related Events</b>	<b>16</b>
<b>Acknowledgments</b>	<b>17</b>

---

## Welcome from the Program Directors

Dear Colleagues,

We are pleased to welcome you to the HIV Prevention Review Meeting!

HIV prevention has entered an exciting new era. The past decade has brought significant advances in HIV prevention, with proof of concept that antiretroviral agents, when used as a treatment or pre-exposure prophylaxis (PrEP), prevent HIV transmission/acquisition among multiple populations at risk for HIV infection. More recently, we also have proof of concept that broadly neutralizing antibodies can provide protection against HIV acquisition against sensitive viruses. However, there are many more advances developing in the field.



This meeting will explore the latest information about a variety of HIV prevention topics, including:

- A state-of-the-art update on the HIV vaccine landscape
- Recent clinical trials of PrEP
- Pharmacokinetics, clinical results, and resistance profiles of breakthrough infections in the long-acting injectable cabotegravir PrEP trials
- The newest agents and methods of PrEP delivery currently under development

This meeting will close with a roundtable discussion, including some of the world's leading experts in PrEP discussing the future of HIV prevention. Pose your questions to the experts in this truly global discussion!

This expert review meeting will explore the implications of the new data for you and your clinical practice, and will show how new research is helping to move HIV prevention forward.

We look forward to (virtually) meeting you!

Sincerely,

Susan & Mauro



**Susan Buchbinder, MD**

University of California, San Francisco / Bridge HIV,  
United States



**Mauro Schechter, MD, PhD**

Federal University of Rio de Janeiro,  
Brazil



# Practical Information

## Certificate of Attendance

Certificates of attendance will be sent by e-mail when you complete the post-meeting survey after the completion of the meeting.

## Feedback

Your feedback is very valuable to us and enables us to further improve this meeting. After the meeting, a survey will be sent to you via email, with questions to improve this meeting.

## Presentations and Webcasts

Webcasts of the presentations along with the PDF presentations will be posted as webcasts on [www.AcademicMedicalEducation.com](http://www.AcademicMedicalEducation.com) three weeks after the meeting.



## Social Media

We encourage you to post news about the HIV Prevention Review Meeting to your social media accounts and tweet about **#HIVPreventionReview** as often as you like during the meeting. You can either post your own tweet to your followers using the hashtag **#HIVPreventionReview** or retweet a message through the official **@Academic\_MedEdu**

## Technical Problems

Should you encounter any technical problems, please contact us at [Weixi.Yuan@amededu.com](mailto:Weixi.Yuan@amededu.com) or via the live support on the virtual meeting portal.

## Time Zones

Times are in Pacific Daylight Time (PDT). If you need to convert the times to your time zone, this website might be of interest to you:  
<https://www.worldtimebuddy.com/>

---

Disclaimer: This meeting aims to offer participants the opportunity to share information. The Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.

## Our Team



**Rikke Rode**  
Project Manager

[Rikke.Rode@amededu.com](mailto:Rikke.Rode@amededu.com)



**Weixi Yuan**  
Project Coordinator

[Weixi.Yuan@amededu.com](mailto:Weixi.Yuan@amededu.com)



# Program

---



# Program

## WEDNESDAY 2 JUNE

*Times are in Pacific Daylight Time (PDT)*

### Opening Session

- 09:00 **Opening Words**  
**Mauro Schechter, MD, PhD**  
Federal University of Rio de Janeiro, Brazil  
**Susan Buchbinder, MD**  
University of California, San Francisco / Bridge HIV, United States
- 09:05 **HIV Vaccine Landscape**  
**Larry Corey, MD**  
Fred Hutchinson Cancer Research Center / University of Washington, United States

### Session 1 Oral PrEP Today – Where Do We Stand?

*Chair: Susan Buchbinder*

- 09:25 **Recent Clinical Trials: What Does the Data Tell Us?**  
**Jean-Michel Molina, MD, PhD**  
Hôpital St. Louis, France
- 09:45 **Q&A**

09:55 **Break**

### Session 2 Session 2: Long-Acting Injectable PrEP

*Chair: Mauro Schechter*

- 10:00 **Pharmacokinetics of LA CAB**  
**Marta Boffito, MD, PhD, FRCP**  
Chelsea and Westminster Hospital London, United Kingdom
- 10:10 **Overview of Clinical Data**  
**Mina Hosseinipour, MD, MPH**  
University of North Carolina at Chapel Hill School of Medicine / UNC Project Malawi, United States / Malawi
- 10:30 **Resistance, Breakthrough, Infections**  
**Raphael Landovitz, MD, MSc**  
University of California, Los Angeles, United States
- 10:50 **What Is on the Horizon in the PrEP Arena?**  
**Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD**  
Desmond Tutu HIV Foundation / University of Cape Town (UCT), South Africa

11:10 **Break**



---

## Roundtable Discussion: Where Is HIV Prevention Going?

*Chair: Mauro Schechter & Susan Buchbinder*

### **Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD**

Desmond Tutu HIV Foundation / University of Cape Town (UCT), South Africa

### **Marta Boffito, MD, PhD, FRCP**

Chelsea and Westminster Hospital London, United Kingdom

### **Simon Collins**

HIV i-Base, United Kingdom

### **Mina Hosseinipour, MD, MPH**

University of North Carolina at Chapel Hill School of Medicine / UNC Project Malawi, United States / Malawi

11:20

### **Raphael Landovitz, MD, MSc**

University of California, Los Angeles, United States

### **Sheena McCormack, MD**

Medical Research Council (MRC), United Kingdom

### **Jean-Michel Molina, MD, PhD**

Hôpital St. Louis, France

### **Nittaya Phanuphak, MD, PhD**

Institute of HIV Research and Innovation, Thailand

### **Jorge Sanchez, MD, MPH**

CITBM - Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Peru

---

## Closing Remarks

### **Closing of the Meeting**

#### **Mauro Schechter, MD, PhD**

12:00 Federal University of Rio de Janeiro, Brazil

#### **Susan Buchbinder, MD**

University of California, San Francisco / Bridge HIV, United States

---

12:05 **End of the Meeting**

---



# Accreditation

The **HIV Prevention Review Meeting 2021**, Utrecht, Netherlands, 02/06/2021-02/06/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **2 European CME credits** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities). Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

## Obtain Your CME Credits

An online survey will be sent out to all attendees at the end of the meeting. After completing the survey, a CME certificate will be sent to your registration email.

If you have any questions regarding claiming CME credits, please contact [Weixi.Yuan@gamededu.com](mailto:Weixi.Yuan@gamededu.com)





# Faculty

---



# Faculty



## SPEAKER

**LINDA-GAIL BEKKER, MBCHB,  
DTMH, DCH, FCP(SA), PhD**

Desmond Tutu HIV Foundation  
/ University of Cape Town  
(UCT),  
South Africa

Linda-Gail Bekker is the Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town and Chief Research Officer of the Desmond Tutu Health Foundation.

She is a physician scientist and infectious disease specialist. Her research interests include programmatic and action research around antiretroviral roll out and TB integration, prevention of HIV in women, youth and MSM. She has led numerous investigator-driven studies in HIV treatment, prevention and tuberculosis.

She is a past president of the International AIDS Society and served as the International Co-Chair of the 9th IAS Conference and 22nd International AIDS Conference and Co-Chaired the Research 4 Prevention Conference that was held in January 2021.

No potential conflict of interest.



## SPEAKER

**MARTA BOFFITO, MD, PhD,  
FRCP**

Chelsea and Westminster  
Hospital London,  
United Kingdom

Marta Boffito is a Consultant Physician, Clinical Research Lead of the Clinical Research Facility and HIV Service Lead at Chelsea and Westminster Hospital, and Reader at Imperial College, London, London UK, where she runs numerous research projects and clinical trials, she consults on complex pharmacological issues, sees patients with HIV (she founded the first HIVover50years clinic in London, UK), and teaches HIV medicine and pharmacology.

She trained in Italy, the USA, and the UK and has a special interest in antiretroviral drug pharmacology: from prevention to treatment. In these areas she contributes to the educational, scientific, and guideline-formulation activities of national bodies including the British HIV Association.

She has published over 150 peer-reviewed articles, editorials, and reviews. She has been involved in capacity building programmes for resource-limited settings (e.g. Uganda) and an applicant on numerous successful collaborative grants.

### Potential conflicts of interest:

Gilead, ViiV, GSK, Valanava, Roche, Novavax, MSD, Janssen, BMS, Mylan, Teva, Cipla





## PROGRAM DIRECTOR

### SUSAN BUCHBINDER, MD

University of California, San Francisco / Bridge HIV, United States

Susan Buchbinder is the Director of Bridge HIV, a grant-funded HIV prevention research unit housed at the San Francisco Department of Public Health. She is also Clinical Professor of Medicine, Epidemiology and Biostatistics at the University of California, San Francisco, where she is an attending physician in the Richard Fine People's Clinic, and teaches in the Advanced Traineeship in Clinical Research Program.

Her HIV research focuses on HIV vaccines, preexposure prophylaxis, broadly neutralizing antibodies, topical microbicides and vaginal rings, and strategies to support their uptake and use, with a focus on racial/ethnic and gender disparities. She is one of the founding members and serves on the Steering Committee of "Getting to Zero San Francisco," an initiative that aims to eliminate new HIV infections, HIV-associated deaths, and HIV stigma.

She has served as Chair of the Conference on Retroviruses and Opportunistic Infections, and the Research 4 Prevention Conferences.

No potential conflict of interest.



## SPEAKER

### SIMON COLLINS

HIV i-Base, United Kingdom

Simon Collins is an HIV positive treatment advocate at i-Base.info which he co-founded in April 2000.

i-Base supports HIV positive people to take an active role in their own health care. For many years he has produced and updated a series of non-technical treatment guides and edits a monthly technical review called HIV Treatment Bulletin (HTB).

Other i-Base services include a treatment information service that answers individual questions by phone, email and online.

Working with Community Advisory Boards he has developed close working relationships with numerous research groups. This included being a community representative on the PARTNER and START studies and the ongoing INSIGHT, RIO and EHVA studies.

In addition to i-Base publications he is a contributing author to many published papers, guidelines and conference presentations.

No potential conflict of interest.



# Faculty



**SPEAKER**

**LARRY COREY, MD**

Fred Hutchinson Cancer Research Center / University of Washington, United States

Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of the Fred Hutchinson Cancer Research Center. His research focuses on herpes viruses, HIV, the novel coronavirus and other viral infections, including those associated with cancer.

He is the founder and principal investigator of the HIV Vaccine Trials Network, or HVTN, which conducts studies of HIV vaccines at over 80 clinical trials sites in 16 countries on five continents. Under his leadership, the HVTN has become the model for global, collaborative research. Dr. Corey is also the principal investigator of the Fred Hutch-based operations center of the COVID-19 Prevention Network (CoVPN) and co-leads the Network's COVID-19 vaccine testing pipeline. The CoVPN is carrying out the large Operation Warp Speed portfolio of COVID-19 vaccines and monoclonal antibodies intended to protect people from COVID-19.

Dr. Corey is a member of the US National Academy of Medicine and the American Academy of Arts and Sciences, and was the recipient of the Parran Award for his work in HSV-2, the American Society of Microbiology Cubist Award for his work on antivirals, and the University of Michigan Medical School Distinguished Alumnus Award.

He is one of the most highly cited biomedical researchers in the last 20 years and is the author, coauthor or editor of over 1000 scientific publications.

No potential conflict of interest.



**SPEAKER**

**MINA HOSSEINIPOUR, MD, MPH**

University of North Carolina at Chapel Hill School of Medicine / UNC Project Malawi, United States / Malawi

Mina Hosseinipour is an infectious disease physician and epidemiologist who has lived and worked in Malawi since 2001. She is a Professor of Medicine at UNC-CH, the Scientific director of the UNCPM, and the Co-Principal investigator of the DAIDS sponsored UNC Global Clinical Trials Unit.

She is the Principal Investigator for three NIH funded implementation science capacity building grants and is the co-Chair of the HPTN 084 study evaluating Cabotegravir LA for HIV prevention in women.

Her research over the years has encompassed treatment of HIV and its complications, HIV prevention and PMTCT. She has collaborated with and mentored junior investigators in the evaluation of partner involvement in PMTCT, engagement in care of female sex workers, and evaluation of care delivery services for AGYW.

No potential conflict of interest.





**SPEAKER**

**RAPHAEL LANDOVITZ, MD, MSc**

University of California, Los Angeles, United States

Raphael Landovitz received his BA in Chemistry from Princeton University (Princeton, New Jersey, USA), and received his medical degree from Harvard Medical School (Boston, Massachusetts, USA). Following this, he completed an internship, residency, and served as Chief Resident in Internal Medicine at Brigham and Women's Hospital (Boston, Massachusetts, USA) and an Infectious Diseases fellowship with Brigham and Women's Hospital and Massachusetts General Hospital (Boston, Massachusetts, USA).

He served as Medical Co-Director of the Vietnam-CDC-Harvard Medical School-AIDS-Partnership (VCHAP), helping to train Vietnamese physicians in HIV care and treatment. In 2006 he joined the UCLA Center for Clinical AIDS Research and Education (CARE), where he is an infectious disease and HIV clinician and clinical investigator.

His research interests include HIV prevention (including pre- and post-exposure prophylaxis and other combination prevention strategies) and the impact of such prevention interventions on risk behavior. Dr. Landovitz works with the United States National Institutes of Health (NIH)-funded Division of AIDS (DAIDS) clinical trials networks for HIV therapeutics and HIV Prevention.

He has led numerous clinical trials, and currently leads the NIH trials developing long-acting injectable cabotegravir for HIV prevention. In 2010, he was awarded the John Carey Young Investigator Award by the AIDS Clinical Trials Group in 2010, and the American Association of HIV Medicine Research Award in 2017.

**Potential conflicts of interest:**

Gilead, Merck, Janssen, Roche



**SPEAKER**

**SHEENA MCCORMACK, MD**

Medical Research Council (MRC), United Kingdom

Sheena McCormack is a Clinical Epidemiologist who has worked on HIV vaccine, microbicide and PrEP trials since 1994. She is a Senior Clinical Scientist at the MRC Clinical Trials Unit at UCL, was awarded a Chair at Imperial College in 2012, and at University College London in 2017. Her clinical job is at 56 Dean Street, a sexual health clinic in Soho.

She led the PROUD PrEP study conducted in MSM attending sexual health clinics in England, which reported early due to unexpectedly high incidence in those without access to PrEP and an 86% reduction in those with access to PrEP. Since then she has focused on access for all who need PrEP in the UK and more broadly in Europe.

She is currently involved in a large PrEP trial in England, an internet trial of self-testing, prophylactic and therapeutic vaccine trials in Europe and Sub-Saharan Africa and COVID-19 vaccine trials.

**Potential conflicts of interest:**

Gilad, Funds for my time and to reimburse travel paid to UCL for various talks at the invitation of independent organisations.



# Faculty



**SPEAKER**

**JEAN-MICHEL MOLINA, MD, PhD**

Hôpital St. Louis,  
France

Jean-Michel Molina is Professor of Infectious Diseases at the University of Paris Diderot - Paris 7, and Head of the Infectious Diseases Department at the Saint-Louis Hospital in Paris.

The Department of Infectious Diseases at the Saint-Louis Hospital, is mainly involved in the care of immunocompromised patients, patients with HIV-infection and patients with bone marrow and renal transplant patients, haematologic malignancies and cancers. Professor Molina's primary clinical research interest lies in the area of HIV infection, initially the treatment of opportunistic infections, then the treatment of HIV-infection. He has been involved in a number of studies assessing new drugs or new strategies for the treatment of HIV infection. A cohort of more than 3,500 patients with HIV-infection is followed in his department and is involved in this clinical research. He is also a member of the INSERM U941 team involved in HIV basic research the Saint-Louis hospital.

Professor Molina has authored many papers in a wide variety of scientific journals, including Clinical Infectious Diseases, the Journal of Infectious Diseases, the New England Journal of Medicine, the Lancet, and AIDS.

He is the Chair of the Clinical Trial Group at the French National Agency for AIDS Research (ANRS), where multicentre clinical trials are reviewed and implemented in France. Working with the ANRS, Professor Molina has been the principal investigator of a number of clinical trials in HIV-infected patients.

More recently, Professor Molina has broadened his field of interest to the prevention of HIV infection with antiretrovirals and is leading the ANRS IPERGAY PrEP trial in men who have sex with men in France and Canada.

**Potential conflicts of interest:**

Gilead, Merck, Janssen, ViiV Healthcare



**SPEAKER**

**NITTAYA PHANUPHAK, MD, PhD**

Institute of HIV Research and  
Innovation,  
Thailand

Nittaya Phanuphak is currently the Executive Director at the Institute of HIV Research and Innovation in Bangkok, Thailand. She has deep interest in HIV prevention and key populations (KP), especially around the use of Key Population-Led Health Service (KPLHS) approaches to enhance access to HIV testing, prevention and treatment among men who have sex with men and transgender women. She currently works actively with community and government partners to establish a national technical assistance platform to support the accreditation and legalization of KP lay providers to ensure KPLHS sustainability through domestic financing mechanism.

In 2015, she supported the establishment of the Tangerine Community Health Center at TRCARC using integrated hormone therapy and sexual health service approach to effectively bring almost 3,000 transgender women (TGW) and transgender men into services over a 3-year period. The model is currently being expanded to community-based organizations (CBOs), as well as public and private clinics, working with transgender people in the region.

**Potential conflicts of interest:**

Gilead, Merck, ViiV Healthcare





## SPEAKER

### **JORGE SANCHEZ, MD, MPH**

CITBM - Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Peru

Jorge Sanchez is an infectious diseases specialist from Universidad Peruana Cayetano Heredia with a master's degree in Public Health from the University of Washington.

From 1992 to 2000 worked as a University of Washington consultant in HIV/STI research and training, with a focus on Central America and Caribbean countries. In 2000, Dr. Sanchez was awarded by the US NIH/NIAID/DAIDS as Principal Investigator of the University of Washington sub-site in Peru, to serve the HIV Prevention Trial Network (HPTN) and the HIV Vaccine Trial Network (HVTN).

In 2003 the focus of the Peruvian sites was expanded to implement research for the Adult AIDS Clinical Trial Network. In 2006, he received the award to be the Principal Investigator of the IMPACTA PERU Clinical Trial Unit (CTU).

Dr. Sanchez has been deeply involved in the development and implementation of the research agenda of the DAIDS-funded Networks serving as protocol team member of several study teams and member of several network research committees. He has been a member of the HPTN Executive Committee from 2004 to 2005; a member of the ACTG Executive Committee from 2005 to 2007, from 2011 to 2013, and from 2019 until now

No potential conflict of interest.



## PROGRAM DIRECTOR

### **MAURO SCHECHTER, MD, PhD**

Federal University of Rio de Janeiro, Brazil

Mauro Schechter is professor of Infectious Diseases at the Department of Preventive Medicine of the Federal University of Rio de Janeiro, Brazil. He is also Adjunct Professor of Epidemiology at the Graduate School of Public Health, University of Pittsburgh, and Associate in the Department of International Health, Bloomberg School of Hygiene and Public Health, Johns Hopkins University.

Dr. Schechter serves or has served on numerous Advisory Boards and Blue-Ribbon Panels, including the AIDS Clinical Trials Group (ACTG) Executive and Scientific Agenda Steering Committees, the Scientific Council of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), the Scientific Advisory Committees of the South African AIDS Vaccine Initiative (SAAVI), and Clinical Trials Committee of the International AIDS Vaccine Initiative (IAVI).

The author of over 200 peer-reviewed articles, Dr. Schechter is the Epidemiology Section Editor, AIDS Research and Human Retroviruses Journal. His primary research interest is preventing and treating HIV/AIDS in different settings.

Dr. Schechter earned his M.D. at the Federal University of Rio de Janeiro and his PhD at the London School of Hygiene & Tropical Medicine, University of London. He was a Research Associate at the Rockefeller University, New York, and a Research Assistant Professor at New York University School of Medicine.

#### Potential conflicts of interest:

Gilead, GSK, Merck, ViiV Healthcare





# HIV PREVENTION

---

## SUMMIT 2021

**VIRTUAL** | 1 - 2 DECEMBER 2021

The **HIV Prevention Summit 2021**, the second meeting in the HIV Prevention Series, will take place in December 2021.

This program is designed to promote understanding among physicians, nurses, policymakers, and community advocates on antiretroviral drugs for prevention, novel formulations and devices, implementation strategies, and individual and community-based behavioral aspects of prevention, as well as insights into the vaccine landscape and prospects of monoclonal antibodies for HIV prevention. The universal educational needs regarding existing and novel prevention approaches will be addressed in the truly global context of the HIV epidemic.

Registration to this meeting is waived for all academic registrants including representatives from universities, hospitals, other educational institutes, NGOs, and government agencies.

Register here: <https://virology.eventsair.com/hiv-prevention-summit-2021/registration-page>

Read more here: <https://academicmedicaleducation.com/meeting/hiv-prevention-summit-2021>





# Acknowledgements

## ENDORSED

**ANOVA**  
HEALTH INSTITUTE



**le Réseau**  
Réseau canadien  
pour les essais VIH des IR

